nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—migraine—Prednisone—multiple sclerosis	0.58	1	CpDpCtD
Dihydroergotamine—ABCB1—Methylprednisolone—multiple sclerosis	0.026	0.124	CbGbCtD
Dihydroergotamine—CYP3A4—Fingolimod—multiple sclerosis	0.0242	0.115	CbGbCtD
Dihydroergotamine—HTR1B—trigeminal nucleus—multiple sclerosis	0.022	0.254	CbGeAlD
Dihydroergotamine—HTR1D—trigeminal nucleus—multiple sclerosis	0.0213	0.246	CbGeAlD
Dihydroergotamine—ABCB1—Mitoxantrone—multiple sclerosis	0.019	0.0901	CbGbCtD
Dihydroergotamine—ABCB1—Betamethasone—multiple sclerosis	0.0169	0.0803	CbGbCtD
Dihydroergotamine—ABCB1—Prednisolone—multiple sclerosis	0.0167	0.0793	CbGbCtD
Dihydroergotamine—ABCB1—Prednisone—multiple sclerosis	0.0157	0.0749	CbGbCtD
Dihydroergotamine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0156	0.074	CbGbCtD
Dihydroergotamine—HTR1D—meninx—multiple sclerosis	0.0142	0.163	CbGeAlD
Dihydroergotamine—CYP3A4—Triamcinolone—multiple sclerosis	0.0118	0.0561	CbGbCtD
Dihydroergotamine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0114	0.054	CbGbCtD
Dihydroergotamine—CYP3A4—Betamethasone—multiple sclerosis	0.0101	0.0481	CbGbCtD
Dihydroergotamine—CYP3A4—Prednisolone—multiple sclerosis	0.00999	0.0475	CbGbCtD
Dihydroergotamine—ABCB1—Dexamethasone—multiple sclerosis	0.00983	0.0467	CbGbCtD
Dihydroergotamine—CYP3A4—Prednisone—multiple sclerosis	0.00943	0.0449	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—multiple sclerosis	0.0079	0.0376	CbGbCtD
Dihydroergotamine—CYP3A4—Dexamethasone—multiple sclerosis	0.00589	0.028	CbGbCtD
Dihydroergotamine—HTR1B—trigeminal nerve—multiple sclerosis	0.00579	0.0668	CbGeAlD
Dihydroergotamine—HTR1D—trigeminal nerve—multiple sclerosis	0.00561	0.0647	CbGeAlD
Dihydroergotamine—ADRA2A—peripheral nervous system—multiple sclerosis	0.00153	0.0177	CbGeAlD
Dihydroergotamine—HTR1B—brainstem—multiple sclerosis	0.000908	0.0105	CbGeAlD
Dihydroergotamine—HTR1D—brainstem—multiple sclerosis	0.000879	0.0101	CbGeAlD
Dihydroergotamine—HTR6—nervous system—multiple sclerosis	0.000789	0.0091	CbGeAlD
Dihydroergotamine—HTR6—central nervous system—multiple sclerosis	0.00076	0.00876	CbGeAlD
Dihydroergotamine—HTR1A—brainstem—multiple sclerosis	0.000733	0.00845	CbGeAlD
Dihydroergotamine—HTR6—brain—multiple sclerosis	0.000603	0.00696	CbGeAlD
Dihydroergotamine—HTR1B—midbrain—multiple sclerosis	0.000578	0.00667	CbGeAlD
Dihydroergotamine—HTR1B—spinal cord—multiple sclerosis	0.000564	0.00651	CbGeAlD
Dihydroergotamine—HTR1D—midbrain—multiple sclerosis	0.00056	0.00646	CbGeAlD
Dihydroergotamine—HTR1B—nervous system—multiple sclerosis	0.000476	0.00549	CbGeAlD
Dihydroergotamine—HTR1A—midbrain—multiple sclerosis	0.000467	0.00538	CbGeAlD
Dihydroergotamine—HTR1D—nervous system—multiple sclerosis	0.00046	0.00531	CbGeAlD
Dihydroergotamine—HTR1B—central nervous system—multiple sclerosis	0.000458	0.00528	CbGeAlD
Dihydroergotamine—HTR1A—spinal cord—multiple sclerosis	0.000455	0.00525	CbGeAlD
Dihydroergotamine—HTR1D—central nervous system—multiple sclerosis	0.000443	0.00511	CbGeAlD
Dihydroergotamine—HTR2B—nervous system—multiple sclerosis	0.000428	0.00494	CbGeAlD
Dihydroergotamine—HTR2B—central nervous system—multiple sclerosis	0.000412	0.00476	CbGeAlD
Dihydroergotamine—HTR1A—nervous system—multiple sclerosis	0.000384	0.00443	CbGeAlD
Dihydroergotamine—HTR1A—central nervous system—multiple sclerosis	0.000369	0.00426	CbGeAlD
Dihydroergotamine—HTR1B—brain—multiple sclerosis	0.000364	0.00419	CbGeAlD
Dihydroergotamine—HTR1A—cerebellum—multiple sclerosis	0.000361	0.00417	CbGeAlD
Dihydroergotamine—ADRA2A—medulla oblongata—multiple sclerosis	0.000358	0.00413	CbGeAlD
Dihydroergotamine—HTR1D—brain—multiple sclerosis	0.000352	0.00406	CbGeAlD
Dihydroergotamine—HTR2B—brain—multiple sclerosis	0.000327	0.00378	CbGeAlD
Dihydroergotamine—ADRA2A—midbrain—multiple sclerosis	0.000327	0.00377	CbGeAlD
Dihydroergotamine—ADRA2A—spinal cord—multiple sclerosis	0.000319	0.00368	CbGeAlD
Dihydroergotamine—HTR1A—brain—multiple sclerosis	0.000293	0.00338	CbGeAlD
Dihydroergotamine—ABCB1—retina—multiple sclerosis	0.000276	0.00318	CbGeAlD
Dihydroergotamine—ADRA2A—nervous system—multiple sclerosis	0.000269	0.0031	CbGeAlD
Dihydroergotamine—ADRA2A—central nervous system—multiple sclerosis	0.000259	0.00299	CbGeAlD
Dihydroergotamine—ADRA2A—cerebellum—multiple sclerosis	0.000253	0.00292	CbGeAlD
Dihydroergotamine—CYP3A4—nervous system—multiple sclerosis	0.000212	0.00244	CbGeAlD
Dihydroergotamine—ADRA2A—brain—multiple sclerosis	0.000206	0.00237	CbGeAlD
Dihydroergotamine—CYP3A4—central nervous system—multiple sclerosis	0.000204	0.00235	CbGeAlD
Dihydroergotamine—ABCB1—medulla oblongata—multiple sclerosis	0.000199	0.0023	CbGeAlD
Dihydroergotamine—ABCB1—midbrain—multiple sclerosis	0.000182	0.0021	CbGeAlD
Dihydroergotamine—ABCB1—spinal cord—multiple sclerosis	0.000178	0.00205	CbGeAlD
Dihydroergotamine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000158	0.00176	CcSEcCtD
Dihydroergotamine—Somnolence—Mitoxantrone—multiple sclerosis	0.000158	0.00176	CcSEcCtD
Dihydroergotamine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000156	0.00174	CcSEcCtD
Dihydroergotamine—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000154	0.00172	CcSEcCtD
Dihydroergotamine—Hypertension—Prednisolone—multiple sclerosis	0.000154	0.00171	CcSEcCtD
Dihydroergotamine—Fatigue—Mitoxantrone—multiple sclerosis	0.000153	0.0017	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000152	0.00169	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000152	0.00169	CcSEcCtD
Dihydroergotamine—Pain—Mitoxantrone—multiple sclerosis	0.000152	0.00169	CcSEcCtD
Dihydroergotamine—Diarrhoea—Azathioprine—multiple sclerosis	0.00015	0.00167	CcSEcCtD
Dihydroergotamine—Discomfort—Prednisolone—multiple sclerosis	0.00015	0.00167	CcSEcCtD
Dihydroergotamine—ABCB1—nervous system—multiple sclerosis	0.00015	0.00173	CbGeAlD
Dihydroergotamine—Malaise—Triamcinolone—multiple sclerosis	0.000148	0.00165	CcSEcCtD
Dihydroergotamine—Malaise—Methylprednisolone—multiple sclerosis	0.000148	0.00164	CcSEcCtD
Dihydroergotamine—Vertigo—Triamcinolone—multiple sclerosis	0.000147	0.00164	CcSEcCtD
Dihydroergotamine—Vertigo—Methylprednisolone—multiple sclerosis	0.000147	0.00164	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000146	0.00163	CcSEcCtD
Dihydroergotamine—Oedema—Prednisolone—multiple sclerosis	0.000146	0.00162	CcSEcCtD
Dihydroergotamine—Dizziness—Azathioprine—multiple sclerosis	0.000145	0.00162	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000145	0.00162	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000145	0.00161	CcSEcCtD
Dihydroergotamine—ABCB1—central nervous system—multiple sclerosis	0.000144	0.00166	CbGeAlD
Dihydroergotamine—Shock—Prednisolone—multiple sclerosis	0.000143	0.00159	CcSEcCtD
Dihydroergotamine—Tachycardia—Prednisolone—multiple sclerosis	0.000142	0.00158	CcSEcCtD
Dihydroergotamine—Hypertension—Triamcinolone—multiple sclerosis	0.000142	0.00158	CcSEcCtD
Dihydroergotamine—Hypertension—Methylprednisolone—multiple sclerosis	0.000141	0.00157	CcSEcCtD
Dihydroergotamine—Urticaria—Mitoxantrone—multiple sclerosis	0.000141	0.00157	CcSEcCtD
Dihydroergotamine—ABCB1—cerebellum—multiple sclerosis	0.000141	0.00163	CbGeAlD
Dihydroergotamine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000141	0.00157	CcSEcCtD
Dihydroergotamine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00014	0.00156	CcSEcCtD
Dihydroergotamine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.00014	0.00156	CcSEcCtD
Dihydroergotamine—Myalgia—Triamcinolone—multiple sclerosis	0.00014	0.00156	CcSEcCtD
Dihydroergotamine—Vomiting—Azathioprine—multiple sclerosis	0.00014	0.00155	CcSEcCtD
Dihydroergotamine—Arthralgia—Methylprednisolone—multiple sclerosis	0.000139	0.00155	CcSEcCtD
Dihydroergotamine—Myalgia—Methylprednisolone—multiple sclerosis	0.000139	0.00155	CcSEcCtD
Dihydroergotamine—Anxiety—Methylprednisolone—multiple sclerosis	0.000139	0.00155	CcSEcCtD
Dihydroergotamine—Rash—Azathioprine—multiple sclerosis	0.000139	0.00154	CcSEcCtD
Dihydroergotamine—Dermatitis—Azathioprine—multiple sclerosis	0.000138	0.00154	CcSEcCtD
Dihydroergotamine—Flushing—Prednisone—multiple sclerosis	0.000138	0.00154	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000138	0.00154	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000138	0.00154	CcSEcCtD
Dihydroergotamine—Discomfort—Triamcinolone—multiple sclerosis	0.000138	0.00154	CcSEcCtD
Dihydroergotamine—Discomfort—Methylprednisolone—multiple sclerosis	0.000138	0.00153	CcSEcCtD
Dihydroergotamine—Headache—Azathioprine—multiple sclerosis	0.000138	0.00153	CcSEcCtD
Dihydroergotamine—Dry mouth—Triamcinolone—multiple sclerosis	0.000137	0.00152	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—multiple sclerosis	0.000135	0.0015	CcSEcCtD
Dihydroergotamine—Confusional state—Methylprednisolone—multiple sclerosis	0.000135	0.0015	CcSEcCtD
Dihydroergotamine—Malaise—Betamethasone—multiple sclerosis	0.000134	0.00149	CcSEcCtD
Dihydroergotamine—Malaise—Dexamethasone—multiple sclerosis	0.000134	0.00149	CcSEcCtD
Dihydroergotamine—Oedema—Triamcinolone—multiple sclerosis	0.000134	0.00149	CcSEcCtD
Dihydroergotamine—Vertigo—Dexamethasone—multiple sclerosis	0.000134	0.00149	CcSEcCtD
Dihydroergotamine—Vertigo—Betamethasone—multiple sclerosis	0.000134	0.00149	CcSEcCtD
Dihydroergotamine—Shock—Triamcinolone—multiple sclerosis	0.000132	0.00147	CcSEcCtD
Dihydroergotamine—Insomnia—Prednisolone—multiple sclerosis	0.000132	0.00147	CcSEcCtD
Dihydroergotamine—Shock—Methylprednisolone—multiple sclerosis	0.000132	0.00146	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—multiple sclerosis	0.000131	0.00146	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000131	0.00146	CcSEcCtD
Dihydroergotamine—Paraesthesia—Prednisolone—multiple sclerosis	0.000131	0.00146	CcSEcCtD
Dihydroergotamine—Tachycardia—Triamcinolone—multiple sclerosis	0.000131	0.00145	CcSEcCtD
Dihydroergotamine—Nausea—Azathioprine—multiple sclerosis	0.00013	0.00145	CcSEcCtD
Dihydroergotamine—Tachycardia—Methylprednisolone—multiple sclerosis	0.00013	0.00145	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.00013	0.00144	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000129	0.00144	CcSEcCtD
Dihydroergotamine—Hypertension—Dexamethasone—multiple sclerosis	0.000129	0.00143	CcSEcCtD
Dihydroergotamine—Hypertension—Betamethasone—multiple sclerosis	0.000129	0.00143	CcSEcCtD
Dihydroergotamine—Asthenia—Mitoxantrone—multiple sclerosis	0.000127	0.00142	CcSEcCtD
Dihydroergotamine—Myalgia—Dexamethasone—multiple sclerosis	0.000127	0.00141	CcSEcCtD
Dihydroergotamine—Myalgia—Betamethasone—multiple sclerosis	0.000127	0.00141	CcSEcCtD
Dihydroergotamine—Anxiety—Dexamethasone—multiple sclerosis	0.000126	0.00141	CcSEcCtD
Dihydroergotamine—Anxiety—Betamethasone—multiple sclerosis	0.000126	0.00141	CcSEcCtD
Dihydroergotamine—Discomfort—Betamethasone—multiple sclerosis	0.000125	0.00139	CcSEcCtD
Dihydroergotamine—Discomfort—Dexamethasone—multiple sclerosis	0.000125	0.00139	CcSEcCtD
Dihydroergotamine—Hypotension—Methylprednisolone—multiple sclerosis	0.000125	0.00139	CcSEcCtD
Dihydroergotamine—Pain—Prednisolone—multiple sclerosis	0.000125	0.00139	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—multiple sclerosis	0.000124	0.00138	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000122	0.00136	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000122	0.00136	CcSEcCtD
Dihydroergotamine—Oedema—Betamethasone—multiple sclerosis	0.000122	0.00135	CcSEcCtD
Dihydroergotamine—Oedema—Dexamethasone—multiple sclerosis	0.000122	0.00135	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000122	0.00135	CcSEcCtD
Dihydroergotamine—Insomnia—Triamcinolone—multiple sclerosis	0.000121	0.00135	CcSEcCtD
Dihydroergotamine—Insomnia—Methylprednisolone—multiple sclerosis	0.000121	0.00135	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Prednisone—multiple sclerosis	0.00012	0.00134	CcSEcCtD
Dihydroergotamine—Paraesthesia—Triamcinolone—multiple sclerosis	0.00012	0.00134	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Prednisolone—multiple sclerosis	0.00012	0.00134	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00012	0.00134	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—multiple sclerosis	0.00012	0.00134	CcSEcCtD
Dihydroergotamine—Shock—Dexamethasone—multiple sclerosis	0.00012	0.00133	CcSEcCtD
Dihydroergotamine—Shock—Betamethasone—multiple sclerosis	0.00012	0.00133	CcSEcCtD
Dihydroergotamine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000119	0.00133	CcSEcCtD
Dihydroergotamine—Agitation—Prednisone—multiple sclerosis	0.000119	0.00133	CcSEcCtD
Dihydroergotamine—Tachycardia—Dexamethasone—multiple sclerosis	0.000119	0.00132	CcSEcCtD
Dihydroergotamine—Tachycardia—Betamethasone—multiple sclerosis	0.000119	0.00132	CcSEcCtD
Dihydroergotamine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000118	0.00131	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000118	0.00131	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000118	0.00131	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000118	0.00131	CcSEcCtD
Dihydroergotamine—Malaise—Prednisone—multiple sclerosis	0.000117	0.0013	CcSEcCtD
Dihydroergotamine—Vertigo—Prednisone—multiple sclerosis	0.000117	0.0013	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—multiple sclerosis	0.000116	0.00129	CcSEcCtD
Dihydroergotamine—Anorexia—Betamethasone—multiple sclerosis	0.000116	0.00129	CcSEcCtD
Dihydroergotamine—Anorexia—Dexamethasone—multiple sclerosis	0.000116	0.00129	CcSEcCtD
Dihydroergotamine—Urticaria—Prednisolone—multiple sclerosis	0.000116	0.00129	CcSEcCtD
Dihydroergotamine—Fatigue—Triamcinolone—multiple sclerosis	0.000116	0.00129	CcSEcCtD
Dihydroergotamine—Fatigue—Methylprednisolone—multiple sclerosis	0.000115	0.00128	CcSEcCtD
Dihydroergotamine—Pain—Triamcinolone—multiple sclerosis	0.000115	0.00127	CcSEcCtD
Dihydroergotamine—ABCB1—brain—multiple sclerosis	0.000115	0.00132	CbGeAlD
Dihydroergotamine—Hypotension—Dexamethasone—multiple sclerosis	0.000114	0.00126	CcSEcCtD
Dihydroergotamine—Hypotension—Betamethasone—multiple sclerosis	0.000114	0.00126	CcSEcCtD
Dihydroergotamine—Vomiting—Mitoxantrone—multiple sclerosis	0.000113	0.00126	CcSEcCtD
Dihydroergotamine—Hypertension—Prednisone—multiple sclerosis	0.000112	0.00125	CcSEcCtD
Dihydroergotamine—Rash—Mitoxantrone—multiple sclerosis	0.000112	0.00125	CcSEcCtD
Dihydroergotamine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000112	0.00124	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—multiple sclerosis	0.000112	0.00124	CcSEcCtD
Dihydroergotamine—Headache—Mitoxantrone—multiple sclerosis	0.000111	0.00124	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000111	0.00123	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000111	0.00123	CcSEcCtD
Dihydroergotamine—Arthralgia—Prednisone—multiple sclerosis	0.00011	0.00123	CcSEcCtD
Dihydroergotamine—Myalgia—Prednisone—multiple sclerosis	0.00011	0.00123	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00011	0.00123	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00011	0.00123	CcSEcCtD
Dihydroergotamine—Anxiety—Prednisone—multiple sclerosis	0.00011	0.00122	CcSEcCtD
Dihydroergotamine—Insomnia—Betamethasone—multiple sclerosis	0.00011	0.00122	CcSEcCtD
Dihydroergotamine—Insomnia—Dexamethasone—multiple sclerosis	0.00011	0.00122	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000109	0.00122	CcSEcCtD
Dihydroergotamine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000109	0.00121	CcSEcCtD
Dihydroergotamine—Paraesthesia—Betamethasone—multiple sclerosis	0.000109	0.00121	CcSEcCtD
Dihydroergotamine—Discomfort—Prednisone—multiple sclerosis	0.000109	0.00121	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000107	0.00119	CcSEcCtD
Dihydroergotamine—Dyspepsia—Betamethasone—multiple sclerosis	0.000107	0.00119	CcSEcCtD
Dihydroergotamine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000107	0.00119	CcSEcCtD
Dihydroergotamine—Urticaria—Triamcinolone—multiple sclerosis	0.000106	0.00118	CcSEcCtD
Dihydroergotamine—Urticaria—Methylprednisolone—multiple sclerosis	0.000106	0.00118	CcSEcCtD
Dihydroergotamine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000106	0.00118	CcSEcCtD
Dihydroergotamine—Oedema—Prednisone—multiple sclerosis	0.000106	0.00118	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000106	0.00118	CcSEcCtD
Dihydroergotamine—Decreased appetite—Betamethasone—multiple sclerosis	0.000106	0.00118	CcSEcCtD
Dihydroergotamine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000106	0.00118	CcSEcCtD
Dihydroergotamine—Nausea—Mitoxantrone—multiple sclerosis	0.000105	0.00117	CcSEcCtD
Dihydroergotamine—Fatigue—Betamethasone—multiple sclerosis	0.000105	0.00117	CcSEcCtD
Dihydroergotamine—Fatigue—Dexamethasone—multiple sclerosis	0.000105	0.00117	CcSEcCtD
Dihydroergotamine—Shock—Prednisone—multiple sclerosis	0.000104	0.00116	CcSEcCtD
Dihydroergotamine—Pain—Betamethasone—multiple sclerosis	0.000104	0.00116	CcSEcCtD
Dihydroergotamine—Pain—Dexamethasone—multiple sclerosis	0.000104	0.00116	CcSEcCtD
Dihydroergotamine—Tachycardia—Prednisone—multiple sclerosis	0.000103	0.00115	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000102	0.00114	CcSEcCtD
Dihydroergotamine—Anorexia—Prednisone—multiple sclerosis	0.000101	0.00112	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000101	0.00112	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.0001	0.00111	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Betamethasone—multiple sclerosis	0.0001	0.00111	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Betamethasone—multiple sclerosis	9.94e-05	0.00111	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	9.94e-05	0.00111	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Triamcinolone—multiple sclerosis	9.87e-05	0.0011	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methylprednisolone—multiple sclerosis	9.85e-05	0.0011	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—multiple sclerosis	9.78e-05	0.00109	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—multiple sclerosis	9.74e-05	0.00108	CcSEcCtD
Dihydroergotamine—Urticaria—Betamethasone—multiple sclerosis	9.66e-05	0.00107	CcSEcCtD
Dihydroergotamine—Urticaria—Dexamethasone—multiple sclerosis	9.66e-05	0.00107	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	9.65e-05	0.00107	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisolone—multiple sclerosis	9.63e-05	0.00107	CcSEcCtD
Dihydroergotamine—Asthenia—Triamcinolone—multiple sclerosis	9.61e-05	0.00107	CcSEcCtD
Dihydroergotamine—Abdominal pain—Betamethasone—multiple sclerosis	9.61e-05	0.00107	CcSEcCtD
Dihydroergotamine—Body temperature increased—Dexamethasone—multiple sclerosis	9.61e-05	0.00107	CcSEcCtD
Dihydroergotamine—Abdominal pain—Dexamethasone—multiple sclerosis	9.61e-05	0.00107	CcSEcCtD
Dihydroergotamine—Body temperature increased—Betamethasone—multiple sclerosis	9.61e-05	0.00107	CcSEcCtD
Dihydroergotamine—Asthenia—Methylprednisolone—multiple sclerosis	9.59e-05	0.00107	CcSEcCtD
Dihydroergotamine—Insomnia—Prednisone—multiple sclerosis	9.58e-05	0.00107	CcSEcCtD
Dihydroergotamine—Paraesthesia—Prednisone—multiple sclerosis	9.51e-05	0.00106	CcSEcCtD
Dihydroergotamine—Pruritus—Triamcinolone—multiple sclerosis	9.48e-05	0.00105	CcSEcCtD
Dihydroergotamine—Pruritus—Methylprednisolone—multiple sclerosis	9.46e-05	0.00105	CcSEcCtD
Dihydroergotamine—Dyspepsia—Prednisone—multiple sclerosis	9.32e-05	0.00104	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—multiple sclerosis	9.23e-05	0.00103	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—multiple sclerosis	9.23e-05	0.00103	CcSEcCtD
Dihydroergotamine—Decreased appetite—Prednisone—multiple sclerosis	9.2e-05	0.00102	CcSEcCtD
Dihydroergotamine—Rash—Prednisolone—multiple sclerosis	9.19e-05	0.00102	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisolone—multiple sclerosis	9.18e-05	0.00102	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methylprednisolone—multiple sclerosis	9.15e-05	0.00102	CcSEcCtD
Dihydroergotamine—Fatigue—Prednisone—multiple sclerosis	9.13e-05	0.00102	CcSEcCtD
Dihydroergotamine—Headache—Prednisolone—multiple sclerosis	9.13e-05	0.00102	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—multiple sclerosis	9.12e-05	0.00101	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—multiple sclerosis	8.92e-05	0.000993	CcSEcCtD
Dihydroergotamine—Dizziness—Triamcinolone—multiple sclerosis	8.86e-05	0.000986	CcSEcCtD
Dihydroergotamine—Dizziness—Methylprednisolone—multiple sclerosis	8.84e-05	0.000984	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Prednisone—multiple sclerosis	8.72e-05	0.000971	CcSEcCtD
Dihydroergotamine—Asthenia—Betamethasone—multiple sclerosis	8.72e-05	0.00097	CcSEcCtD
Dihydroergotamine—Asthenia—Dexamethasone—multiple sclerosis	8.72e-05	0.00097	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Prednisone—multiple sclerosis	8.66e-05	0.000963	CcSEcCtD
Dihydroergotamine—Nausea—Prednisolone—multiple sclerosis	8.65e-05	0.000963	CcSEcCtD
Dihydroergotamine—Pruritus—Dexamethasone—multiple sclerosis	8.6e-05	0.000957	CcSEcCtD
Dihydroergotamine—Pruritus—Betamethasone—multiple sclerosis	8.6e-05	0.000957	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—multiple sclerosis	8.55e-05	0.000952	CcSEcCtD
Dihydroergotamine—Vomiting—Triamcinolone—multiple sclerosis	8.52e-05	0.000948	CcSEcCtD
Dihydroergotamine—Vomiting—Methylprednisolone—multiple sclerosis	8.5e-05	0.000946	CcSEcCtD
Dihydroergotamine—Rash—Triamcinolone—multiple sclerosis	8.45e-05	0.00094	CcSEcCtD
Dihydroergotamine—Dermatitis—Triamcinolone—multiple sclerosis	8.44e-05	0.000939	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—multiple sclerosis	8.43e-05	0.000938	CcSEcCtD
Dihydroergotamine—Rash—Methylprednisolone—multiple sclerosis	8.43e-05	0.000938	CcSEcCtD
Dihydroergotamine—Dermatitis—Methylprednisolone—multiple sclerosis	8.42e-05	0.000937	CcSEcCtD
Dihydroergotamine—Urticaria—Prednisone—multiple sclerosis	8.41e-05	0.000936	CcSEcCtD
Dihydroergotamine—Headache—Triamcinolone—multiple sclerosis	8.39e-05	0.000934	CcSEcCtD
Dihydroergotamine—Headache—Methylprednisolone—multiple sclerosis	8.37e-05	0.000932	CcSEcCtD
Dihydroergotamine—Body temperature increased—Prednisone—multiple sclerosis	8.37e-05	0.000931	CcSEcCtD
Dihydroergotamine—Abdominal pain—Prednisone—multiple sclerosis	8.37e-05	0.000931	CcSEcCtD
Dihydroergotamine—Diarrhoea—Betamethasone—multiple sclerosis	8.32e-05	0.000925	CcSEcCtD
Dihydroergotamine—Diarrhoea—Dexamethasone—multiple sclerosis	8.32e-05	0.000925	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—multiple sclerosis	8.27e-05	0.00092	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	8.06e-05	0.000897	CcSEcCtD
Dihydroergotamine—Dizziness—Dexamethasone—multiple sclerosis	8.04e-05	0.000894	CcSEcCtD
Dihydroergotamine—Dizziness—Betamethasone—multiple sclerosis	8.04e-05	0.000894	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—multiple sclerosis	8e-05	0.00089	CcSEcCtD
Dihydroergotamine—Nausea—Triamcinolone—multiple sclerosis	7.96e-05	0.000885	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—multiple sclerosis	7.94e-05	0.000884	CcSEcCtD
Dihydroergotamine—Nausea—Methylprednisolone—multiple sclerosis	7.94e-05	0.000883	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—multiple sclerosis	7.89e-05	0.000878	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—multiple sclerosis	7.87e-05	0.000875	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisone—multiple sclerosis	7.8e-05	0.000868	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—multiple sclerosis	7.79e-05	0.000867	CcSEcCtD
Dihydroergotamine—Vomiting—Betamethasone—multiple sclerosis	7.73e-05	0.00086	CcSEcCtD
Dihydroergotamine—Vomiting—Dexamethasone—multiple sclerosis	7.73e-05	0.00086	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—multiple sclerosis	7.69e-05	0.000856	CcSEcCtD
Dihydroergotamine—Rash—Betamethasone—multiple sclerosis	7.66e-05	0.000853	CcSEcCtD
Dihydroergotamine—Rash—Dexamethasone—multiple sclerosis	7.66e-05	0.000853	CcSEcCtD
Dihydroergotamine—Dermatitis—Betamethasone—multiple sclerosis	7.66e-05	0.000852	CcSEcCtD
Dihydroergotamine—Dermatitis—Dexamethasone—multiple sclerosis	7.66e-05	0.000852	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—multiple sclerosis	7.63e-05	0.000849	CcSEcCtD
Dihydroergotamine—Headache—Dexamethasone—multiple sclerosis	7.62e-05	0.000847	CcSEcCtD
Dihydroergotamine—Headache—Betamethasone—multiple sclerosis	7.62e-05	0.000847	CcSEcCtD
Dihydroergotamine—Asthenia—Prednisone—multiple sclerosis	7.6e-05	0.000845	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—multiple sclerosis	7.57e-05	0.000842	CcSEcCtD
Dihydroergotamine—Pruritus—Prednisone—multiple sclerosis	7.49e-05	0.000833	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—multiple sclerosis	7.29e-05	0.000811	CcSEcCtD
Dihydroergotamine—Diarrhoea—Prednisone—multiple sclerosis	7.24e-05	0.000806	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—multiple sclerosis	7.23e-05	0.000805	CcSEcCtD
Dihydroergotamine—Nausea—Dexamethasone—multiple sclerosis	7.22e-05	0.000803	CcSEcCtD
Dihydroergotamine—Nausea—Betamethasone—multiple sclerosis	7.22e-05	0.000803	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—multiple sclerosis	7.03e-05	0.000782	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisone—multiple sclerosis	7e-05	0.000779	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—multiple sclerosis	6.99e-05	0.000778	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—multiple sclerosis	6.99e-05	0.000778	CcSEcCtD
Dihydroergotamine—Vomiting—Prednisone—multiple sclerosis	6.73e-05	0.000749	CcSEcCtD
Dihydroergotamine—Rash—Prednisone—multiple sclerosis	6.68e-05	0.000743	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisone—multiple sclerosis	6.67e-05	0.000742	CcSEcCtD
Dihydroergotamine—Headache—Prednisone—multiple sclerosis	6.63e-05	0.000738	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—multiple sclerosis	6.52e-05	0.000725	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—multiple sclerosis	6.35e-05	0.000706	CcSEcCtD
Dihydroergotamine—Nausea—Prednisone—multiple sclerosis	6.29e-05	0.0007	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—multiple sclerosis	6.26e-05	0.000696	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—multiple sclerosis	6.05e-05	0.000674	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—multiple sclerosis	5.85e-05	0.000651	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—multiple sclerosis	5.63e-05	0.000626	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—multiple sclerosis	5.58e-05	0.000621	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—multiple sclerosis	5.57e-05	0.00062	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—multiple sclerosis	5.54e-05	0.000617	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—multiple sclerosis	5.26e-05	0.000585	CcSEcCtD
Dihydroergotamine—ADRA2A—Signaling Pathways—RGS1—multiple sclerosis	1.7e-05	0.000508	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CXCL10—multiple sclerosis	1.7e-05	0.000508	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PGR—multiple sclerosis	1.69e-05	0.000507	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTGER4—multiple sclerosis	1.69e-05	0.000504	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCR3—multiple sclerosis	1.67e-05	0.000501	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCR3—multiple sclerosis	1.66e-05	0.000497	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PGR—multiple sclerosis	1.66e-05	0.000496	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CD28—multiple sclerosis	1.66e-05	0.000496	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCR3—multiple sclerosis	1.65e-05	0.000493	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CD28—multiple sclerosis	1.65e-05	0.000493	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL3—multiple sclerosis	1.64e-05	0.000492	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CNR1—multiple sclerosis	1.63e-05	0.000488	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCR2—multiple sclerosis	1.63e-05	0.000487	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCR3—multiple sclerosis	1.63e-05	0.000487	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CCR5—multiple sclerosis	1.62e-05	0.000485	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCR2—multiple sclerosis	1.62e-05	0.000484	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CD28—multiple sclerosis	1.61e-05	0.000482	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GPR65—multiple sclerosis	1.61e-05	0.000481	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CCL5—multiple sclerosis	1.61e-05	0.000481	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPC5—multiple sclerosis	1.61e-05	0.00048	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCR2—multiple sclerosis	1.6e-05	0.00048	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL2RA—multiple sclerosis	1.6e-05	0.000478	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCR2—multiple sclerosis	1.58e-05	0.000474	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTGER4—multiple sclerosis	1.58e-05	0.000474	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.58e-05	0.000471	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—POMC—multiple sclerosis	1.57e-05	0.000471	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PGR—multiple sclerosis	1.56e-05	0.000466	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.54e-05	0.000462	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CCL2—multiple sclerosis	1.54e-05	0.000461	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SRM—multiple sclerosis	1.53e-05	0.000459	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—POMC—multiple sclerosis	1.53e-05	0.000458	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCR3—multiple sclerosis	1.53e-05	0.000457	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—POMC—multiple sclerosis	1.52e-05	0.000454	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CD28—multiple sclerosis	1.51e-05	0.000453	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CNR1—multiple sclerosis	1.5e-05	0.00045	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CNR1—multiple sclerosis	1.49e-05	0.000446	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCR2—multiple sclerosis	1.49e-05	0.000445	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—POMC—multiple sclerosis	1.49e-05	0.000445	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CNR1—multiple sclerosis	1.48e-05	0.000443	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR1—multiple sclerosis	1.47e-05	0.00044	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL13—multiple sclerosis	1.47e-05	0.00044	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL10—multiple sclerosis	1.47e-05	0.000439	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CNR1—multiple sclerosis	1.46e-05	0.000437	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCL5—multiple sclerosis	1.46e-05	0.000437	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CCR5—multiple sclerosis	1.45e-05	0.000433	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—IL2RA—multiple sclerosis	1.43e-05	0.000427	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.42e-05	0.000425	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—POMC—multiple sclerosis	1.4e-05	0.000418	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—POMC—multiple sclerosis	1.39e-05	0.000416	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—POMC—multiple sclerosis	1.38e-05	0.000412	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CNR1—multiple sclerosis	1.37e-05	0.000411	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CCL2—multiple sclerosis	1.36e-05	0.000407	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL10—multiple sclerosis	1.35e-05	0.000405	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—POMC—multiple sclerosis	1.35e-05	0.000404	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CCL2—multiple sclerosis	1.35e-05	0.000403	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL10—multiple sclerosis	1.34e-05	0.000402	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL3—multiple sclerosis	1.33e-05	0.000399	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL10—multiple sclerosis	1.33e-05	0.000399	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—RRM1—multiple sclerosis	1.33e-05	0.000398	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CCL2—multiple sclerosis	1.32e-05	0.000395	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCR5—multiple sclerosis	1.32e-05	0.000394	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL10—multiple sclerosis	1.32e-05	0.000394	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL2RA—multiple sclerosis	1.3e-05	0.000388	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—ALB—multiple sclerosis	1.28e-05	0.000384	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTGER4—multiple sclerosis	1.28e-05	0.000384	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—POMC—multiple sclerosis	1.27e-05	0.000379	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PGR—multiple sclerosis	1.26e-05	0.000378	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CCL5—multiple sclerosis	1.26e-05	0.000378	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CCL2—multiple sclerosis	1.24e-05	0.000371	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCR3—multiple sclerosis	1.24e-05	0.000371	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL10—multiple sclerosis	1.24e-05	0.00037	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—TYK2—multiple sclerosis	1.23e-05	0.000369	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CD28—multiple sclerosis	1.23e-05	0.000367	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.23e-05	0.000367	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—TYK2—multiple sclerosis	1.22e-05	0.000366	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.22e-05	0.000366	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCR2—multiple sclerosis	1.21e-05	0.000361	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.2e-05	0.000359	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—TYK2—multiple sclerosis	1.2e-05	0.000359	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CD86—multiple sclerosis	1.18e-05	0.000354	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CD86—multiple sclerosis	1.17e-05	0.000351	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCL5—multiple sclerosis	1.17e-05	0.000349	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCL5—multiple sclerosis	1.16e-05	0.000346	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CD86—multiple sclerosis	1.15e-05	0.000344	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCL5—multiple sclerosis	1.15e-05	0.000343	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.14e-05	0.000342	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CCR5—multiple sclerosis	1.14e-05	0.000341	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCL5—multiple sclerosis	1.13e-05	0.000339	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—POMC—multiple sclerosis	1.13e-05	0.000339	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—IL2—multiple sclerosis	1.13e-05	0.000338	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—TYK2—multiple sclerosis	1.13e-05	0.000337	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—IL2—multiple sclerosis	1.12e-05	0.000336	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	1.12e-05	0.000336	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CNR1—multiple sclerosis	1.11e-05	0.000333	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—BCHE—multiple sclerosis	1.1e-05	0.00033	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—IL2—multiple sclerosis	1.1e-05	0.000329	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.08e-05	0.000323	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.08e-05	0.000323	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CD86—multiple sclerosis	1.08e-05	0.000323	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SPP1—multiple sclerosis	1.08e-05	0.000323	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SPP1—multiple sclerosis	1.07e-05	0.00032	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL5—multiple sclerosis	1.06e-05	0.000318	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCR5—multiple sclerosis	1.05e-05	0.000314	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SPP1—multiple sclerosis	1.05e-05	0.000314	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL3—multiple sclerosis	1.05e-05	0.000314	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCR5—multiple sclerosis	1.04e-05	0.000312	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IL2—multiple sclerosis	1.04e-05	0.000311	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL2RA—multiple sclerosis	1.03e-05	0.00031	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCR5—multiple sclerosis	1.03e-05	0.000309	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—IL2—multiple sclerosis	1.03e-05	0.000309	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—POMC—multiple sclerosis	1.03e-05	0.000308	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL2—multiple sclerosis	1.03e-05	0.000307	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2RA—multiple sclerosis	1.03e-05	0.000307	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCR5—multiple sclerosis	1.02e-05	0.000305	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL2—multiple sclerosis	1.02e-05	0.000305	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2RA—multiple sclerosis	1.02e-05	0.000305	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTGER4—multiple sclerosis	1.01e-05	0.000302	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCL2—multiple sclerosis	1.01e-05	0.000301	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2RA—multiple sclerosis	1.01e-05	0.000301	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL10—multiple sclerosis	1e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL2—multiple sclerosis	9.98e-06	0.000299	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PGR—multiple sclerosis	9.94e-06	0.000297	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPC5—multiple sclerosis	9.89e-06	0.000296	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SPP1—multiple sclerosis	9.85e-06	0.000295	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCR3—multiple sclerosis	9.74e-06	0.000292	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	9.65e-06	0.000289	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCR5—multiple sclerosis	9.58e-06	0.000287	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—APOE—multiple sclerosis	9.55e-06	0.000286	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	9.48e-06	0.000284	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—APOE—multiple sclerosis	9.48e-06	0.000284	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2RA—multiple sclerosis	9.45e-06	0.000283	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL2—multiple sclerosis	9.37e-06	0.00028	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—APOE—multiple sclerosis	9.28e-06	0.000278	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—TYK2—multiple sclerosis	9.14e-06	0.000273	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	8.9e-06	0.000266	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CD86—multiple sclerosis	8.76e-06	0.000262	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	8.75e-06	0.000262	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—APOE—multiple sclerosis	8.72e-06	0.000261	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CD80—multiple sclerosis	8.64e-06	0.000258	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL5—multiple sclerosis	8.63e-06	0.000258	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CD80—multiple sclerosis	8.57e-06	0.000256	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CD80—multiple sclerosis	8.39e-06	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—IL2—multiple sclerosis	8.37e-06	0.00025	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—POMC—multiple sclerosis	8.21e-06	0.000245	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RRM1—multiple sclerosis	8.19e-06	0.000245	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—POMC—multiple sclerosis	8.14e-06	0.000244	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	8.12e-06	0.000243	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	8.08e-06	0.000242	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCL2—multiple sclerosis	8.03e-06	0.00024	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SPP1—multiple sclerosis	7.99e-06	0.000239	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—POMC—multiple sclerosis	7.97e-06	0.000239	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCL2—multiple sclerosis	7.97e-06	0.000238	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	7.96e-06	0.000238	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	7.91e-06	0.000237	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CD80—multiple sclerosis	7.88e-06	0.000236	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	7.88e-06	0.000236	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—MAPK1—multiple sclerosis	7.86e-06	0.000235	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCL2—multiple sclerosis	7.8e-06	0.000233	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—MAPK1—multiple sclerosis	7.8e-06	0.000233	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCR5—multiple sclerosis	7.77e-06	0.000232	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.68e-06	0.00023	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2RA—multiple sclerosis	7.66e-06	0.000229	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—BCHE—multiple sclerosis	7.64e-06	0.000229	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—MAPK1—multiple sclerosis	7.63e-06	0.000228	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL2—multiple sclerosis	7.6e-06	0.000227	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—POMC—multiple sclerosis	7.49e-06	0.000224	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL2—multiple sclerosis	7.33e-06	0.000219	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TYK2—multiple sclerosis	7.29e-06	0.000218	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TYK2—multiple sclerosis	7.23e-06	0.000216	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	7.18e-06	0.000215	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—MAPK1—multiple sclerosis	7.17e-06	0.000215	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TYK2—multiple sclerosis	7.08e-06	0.000212	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—multiple sclerosis	7.07e-06	0.000212	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	6.89e-06	0.000206	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	6.78e-06	0.000203	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TYK2—multiple sclerosis	6.65e-06	0.000199	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—multiple sclerosis	6.65e-06	0.000199	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	6.58e-06	0.000197	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CD80—multiple sclerosis	6.39e-06	0.000191	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	6.28e-06	0.000188	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	6.11e-06	0.000183	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—POMC—multiple sclerosis	6.07e-06	0.000182	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL2—multiple sclerosis	6.07e-06	0.000181	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—multiple sclerosis	6.04e-06	0.000181	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	6.02e-06	0.00018	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—multiple sclerosis	6.02e-06	0.00018	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—multiple sclerosis	5.99e-06	0.000179	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	5.97e-06	0.000179	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	5.94e-06	0.000178	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—multiple sclerosis	5.89e-06	0.000176	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—multiple sclerosis	5.87e-06	0.000175	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	5.81e-06	0.000174	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—multiple sclerosis	5.74e-06	0.000172	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—multiple sclerosis	5.71e-06	0.000171	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—multiple sclerosis	5.7e-06	0.00017	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—multiple sclerosis	5.58e-06	0.000167	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	5.56e-06	0.000166	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—multiple sclerosis	5.54e-06	0.000166	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—multiple sclerosis	5.51e-06	0.000165	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	5.4e-06	0.000161	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—multiple sclerosis	5.24e-06	0.000157	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—multiple sclerosis	5.21e-06	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—multiple sclerosis	5.1e-06	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—multiple sclerosis	5.07e-06	0.000152	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	5.02e-06	0.00015	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—multiple sclerosis	4.96e-06	0.000148	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	4.77e-06	0.000143	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—multiple sclerosis	4.74e-06	0.000142	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—multiple sclerosis	4.73e-06	0.000142	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—multiple sclerosis	4.71e-06	0.000141	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—BCHE—multiple sclerosis	4.71e-06	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—multiple sclerosis	4.7e-06	0.00014	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	4.67e-06	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—multiple sclerosis	4.66e-06	0.000139	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK1—multiple sclerosis	4.64e-06	0.000139	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—multiple sclerosis	4.61e-06	0.000138	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK1—multiple sclerosis	4.61e-06	0.000138	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—multiple sclerosis	4.6e-06	0.000138	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—multiple sclerosis	4.6e-06	0.000137	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	4.57e-06	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK1—multiple sclerosis	4.51e-06	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—multiple sclerosis	4.49e-06	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	4.47e-06	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—multiple sclerosis	4.33e-06	0.00013	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—multiple sclerosis	4.32e-06	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	4.25e-06	0.000127	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	4.24e-06	0.000127	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK1—multiple sclerosis	4.24e-06	0.000127	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—multiple sclerosis	3.95e-06	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	3.78e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—multiple sclerosis	3.6e-06	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—multiple sclerosis	3.57e-06	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—multiple sclerosis	3.54e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	3.53e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	3.51e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—multiple sclerosis	3.51e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	3.5e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—multiple sclerosis	3.46e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	3.43e-06	0.000103	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	3.34e-06	9.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—multiple sclerosis	3.25e-06	9.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	2.97e-06	8.88e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—multiple sclerosis	2.83e-06	8.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	2.76e-06	8.26e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	2.75e-06	8.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	2.7e-06	8.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—multiple sclerosis	2.64e-06	7.9e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—multiple sclerosis	2.43e-06	7.28e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—multiple sclerosis	2.22e-06	6.63e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	2.07e-06	6.21e-05	CbGpPWpGaD
